Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. David J. Tamura

Hematology Oncology | Oncology | Hematology
American Oncology Partners Of Hawaii LLC
500 Ala Moana Blvd, Suite 6230, 
Honolulu, HI 
Accepting New Patients
Offers Telehealth
Advanced in Non-Small Cell Lung Cancer (NSCLC)
American Oncology Partners Of Hawaii LLC
500 Ala Moana Blvd, Suite 6230, 
Honolulu, HI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Tamura is a Hematologist Oncology specialist and an Oncologist in Honolulu, Hawaii. Dr. Tamura is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Paget Disease of the Breast, Aleukemic Leukemia Cutis (ALC), Pleuropulmonary Blastoma, and Breast Cancer. Dr. Tamura is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 4 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in HI
Hospital Affiliations
Kapiolani Medical Center For Women & Children
Adventist Health Castle
The Queens Medical Center
Kuakini Medical Center
Pali Momi Medical Center
Languages Spoken
English
Cantonese
Filipino
Ilocano
Samoan
Vietnamese
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AlohaCare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Hawaii Medical Assurance Association
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

AMERICAN ONCOLOGY PARTNERS OF HAWAII LLC
500 Ala Moana Blvd, Suite 6230, Honolulu, HI 96813

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

1 Total Publications

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Journal: Journal for immunotherapy of cancer
Published: July 11, 2021
Similar Doctors
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Ronald H. Yanagihara
Hematology Oncology | Hematology | Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Ronald H. Yanagihara
Hematology Oncology | Hematology | Oncology

Straub Clinic And Hospital

98 -1005 Moanalua Rd, 
Aiea, HI 
 (7.7 miles away)
808-486-6000
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Yanagihara is a Hematologist Oncology specialist and a Hematologist in Aiea, Hawaii. Dr. Yanagihara is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Pleuropulmonary Blastoma, EGFR Positive Lung Cancer, and Bone Marrow Aspiration. Dr. Yanagihara is currently accepting new patients.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Evan S. Wu
Hematology Oncology | Oncology | Hematology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Evan S. Wu
Hematology Oncology | Oncology | Hematology

Straub Clinic And Hospital

98 -1079 Moanalua Rd, 
Aiea, HI 
 (7.5 miles away)
808-486-6000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Evan Wu is a Hematologist Oncology specialist and an Oncologist in Aiea, Hawaii. Dr. Wu is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and ALK-Positive Non-Small Cell Lung Cancer.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Shaun C. Donegan
Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Shaun C. Donegan
Oncology

Queens University Medical Group

1380 Lusitana St, Suite 913, 
Honolulu, HI 
 (0.8 miles away)
808-691-8521
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shaun Donegan is an Oncologist in Honolulu, Hawaii. Dr. Donegan is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Large-Cell Lung Carcinoma, and Squamous Cell Lung Carcinoma. Dr. Donegan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tamura's expertise for a condition
ConditionClose
    View All 67 Advanced Conditions
    View All 152 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile